

1 **Nasopharyngeal Colonization, Associated Factors and Antimicrobial Resistance of**
2 ***Streptococcus pneumoniae* among Children under 5 Years of Age**
3 **in the Southwestern Colombia.**

4 Gustavo Gámez^{a,b,#}, Juan Pablo Rojas^{c,d,e}, Santiago Cardona^b, Juan David Castillo^c, María
5 Alejandra Palacio^a, Luis Fernando Mejía^{c,d}, José Luis Torres^a, Jaime Contreras^c, Laura Mery
6 Muñoz^a, Javier Criales^{c,d}, Luis Felipe Vélez^b, Angélica María Forero^{c,d}, Yulieth Alexandra
7 Zúñiga^b, María Eugenia Cuastumal^{c,d}, Leidy Johanna Acevedo^a, Álvaro de Jesús Molina^{c,d},
8 Johan Alexis Bolivar^b, Alejandro Gómez-Mejía^{f,g}, Jessica Lorena Morales^{a,b}, Sven
9 Hammerschmidt^g.

10 ^aBasic and Applied Microbiology (MICROBA) Research Group, School of Microbiology,
11 University of Antioquia, UdeA, Medellín, Colombia. ^bGenetics, Regeneration and Cancer (GRC)
12 Research Group, University Research Center (SIU), University of Antioquia, UdeA, Medellín,
13 Colombia. ^cClub Noel Children's Clinical Foundation, Cali, Colombia. ^dPediatrics Graduate
14 Program, School of Medicine, University Libre Sectional Cali, Colombia. ^eSchool of Health,
15 Doctoral in Health, Valle University, Cali, Colombia. ^fDepartment of Infectious Diseases and
16 Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091, Zurich,
17 Switzerland. ^gDepartment of Molecular Genetics and Infection Biology, Interfaculty Institute for
18 Genetics and Functional Genomics, Center for Functional Genomics of Microbes, University of
19 Greifswald, Greifswald, Germany.

20 #Corresponding Author: gustavo.gamez@udea.edu.co Escuela de Microbiología (School of
21 Microbiology), Universidad de Antioquia, UdeA, Calle 70 # 52 - 21, 050010 Medellín, Colombia.

22 **Running title:**

23 *S. pneumoniae* carriage among Colombian children.

24 **Abstract:**

25 *Streptococcus pneumoniae* diseases are important causes of children death worldwide.
26 Nasopharyngeal carriage of this pathobiont promotes bacterial spread and infections in the
27 community. Here, a cross-sectional surveillance study was done to determine the proportion of
28 nasopharyngeal colonization, antimicrobial susceptibility profile and associated factors in
29 pediatric outpatients (southwestern Colombia, 2019). Data on factors associated with
30 pneumococcal nasopharyngeal carriage were obtained through survey-based interviews.
31 Nasopharyngeal swabs were collected and bacteria were microbiologically characterized.
32 Antimicrobial susceptibility tests were done by VITEK-2. A logistic regression analysis was
33 performed to examine associated factors. Tests with a *p*-value <0.05 were considered
34 statistically significant. 452 children from the southwestern Colombia were examined and
35 41.8% carried *S. pneumoniae*. A higher pneumococcal carriage frequency was observed
36 among participants <2-years and in individuals belonging to indigenous communities, which
37 were not immunized against pneumococcus, because of lacking established immunization
38 schemes. Additionally, children attending child-care institutions were also highly colonized by
39 pneumococci. *S. pneumoniae* showed 57.7% non-susceptibility to benzyl-penicillin
40 (meningitis-cut); 45.5% intermediate-sensitivity to benzyl-penicillin (oral-cut) and 21.7% to
41 cefotaxime; and resistance to erythromycin (40.7%), tetracycline (36.0%),
42 trimethoprim/sulfamethoxazole (24.9%), clindamycin (24.3%) and ceftriaxone (27.0%). The
43 proportion of 41.8% of participants carrying *S. pneumoniae* shows a scenario with the presence
44 of strains resistant to different antimicrobial agents (MDR and XDR), which constitutes
45 important reservoirs of bacterial transmission by children <5-years in the southwest of
46 Colombia. This situation could potentially lead to an onset of pneumococcal diseases. Hence,

47 the need to expand conjugate pneumococcal immunization in the community and ensure
48 compliance with established immunization schedules.

49 **Keywords:**

50 *Streptococcus pneumoniae*; Nasopharyngeal Carriage; Children under 5 Years of Age;
51 Antimicrobial Susceptibility; Southwest of Colombia.

52 **Introduction:**

53 *Streptococcus pneumoniae*, also known as the pneumococcus, is a Gram-positive bacteria and
54 a normal inhabitant of the nasopharyngeal microbiota of healthy children under 5 years old. The
55 colonization process begins shortly after birth. Although pneumococcal carriage is usually
56 asymptomatic, it can later serve as a reservoir for infections in children, the elderly,
57 immunocompromised people and individuals with underlying diseases. However,
58 *S. pneumoniae* is also a severe pathogen capable of causing diseases including community-
59 acquired pneumonia (CAP), bacteremia, sepsis, meningitis, otitis media and sinusitis (1,2). It is
60 estimated that diseases caused by this bacterium are a major public health problem worldwide,
61 due to high morbidity and mortality rates (3). *S. pneumoniae* is the leading cause of lower
62 respiratory tract infections worldwide, contributing to more deaths than all other etiologies
63 combined (4). Nearly one million children under the age of 5 die each year due to diseases
64 caused by the pneumococcus (2).

65 CAP constitutes a significant proportion of hospital admissions and the global burden of disease
66 in children, being responsible for high mortality rates in infants, mainly in countries with low and
67 medium incomes (5-9). *S. pneumoniae* is the leading cause of bacterial pneumonia, being
68 identified in most cases, and is therefore considered a silent killer of children under 5 years of
69 age (10,11). In Colombia, pneumonia is one of the main causes of mortality with 13 cases

70 100,000 deaths, with *S. pneumoniae* being its main etiological agent with a mortality rate of 3%
71 (12). Likewise, for *S. pneumoniae* in Colombia, the average incidence is 0.28 cases per /
72 100,000 inhabitants, with a lethality between 13% and 27%, even with the appropriate treatment
73 of individuals affected (13,14).

74 The asymptomatic carriage of *S. pneumoniae* has been identified as a prerequisite for the
75 development of invasive and non-invasive diseases, and the carriers serve as sources of
76 transmission of *S. pneumoniae* to other individuals in the community and within hospitals (15-
77 18). Several clinical and demographic characteristics have been positively associated with an
78 increase in the colonization of *S. pneumoniae*, such as infancy, overcrowding, childcare
79 assistance, family size, sibling numbers, poverty, smoking and recent use of antibiotics (19-
80 21). Although nasopharyngeal isolates are not useful for predicting the causative agent of
81 invasive disease in individuals, they do reflect the epidemiological aspects of diseases caused
82 by *S. pneumoniae* in the community (22,23). Bacteria inhabiting the upper respiratory tract of
83 healthy children reflect the strains causing infection that are currently circulating in the
84 community (24). Studies in the recent decades have gradually revealed the connection between
85 pneumococcal carriage and invasive, and mucous infections caused by this pathobiont
86 (15,18,25).

87 For many years, antibiotics such as penicillin and chloramphenicol have been used for the
88 treatment of pneumococcal disease in low- and middle-income countries, given its
89 effectiveness and low costs. Unfortunately, the dramatic increase in resistance to these and
90 other antimicrobial agents worldwide has made the choice of antimicrobial drugs for
91 *S. pneumoniae* infections increasingly difficult and expensive (28-31). Currently, prevention
92 campaigns against pneumococcal infections are carried out using pneumococcal-conjugated
93 vaccines (PCVs), which use the capsular polysaccharides of those specific serotypes most

94 frequently associated with invasive pneumococcal diseases (IPDs) (1,26,27). In Colombia, the
95 7-valent pneumococcal conjugate vaccine was introduced in 2006 in the National Immunization
96 Program, and replaced in 2011 by the 10-valent (2+1 doses).

97 The decrease in several primary risk factors, the implementation of better immunization
98 strategies, and advances in the treatment of pneumococcal infections have made a substantial
99 progress in recent years in reducing the burden of pneumococcal diseases. However, this has
100 not been the same in all geographic regions of the world and more research and intervention
101 efforts are still needed. In addition, nasopharyngeal colonization by antibiotic-resistant
102 *S. pneumoniae* has been steadily increasing, representing potential dangers for the community
103 (4,32,33). In Colombia, and particularly in the southwestern region (Departments of Valle del
104 Cauca, Cauca, Putumayo and Nariño) (Figure 1), epidemiological data on *S. pneumoniae* are
105 extremely limited. Therefore, the objective of this study was to determine the proportion of
106 nasopharyngeal colonization, the profile of antimicrobial susceptibility and the possible
107 associated factors in pediatric outpatients attending the Club Noel Children's Clinical
108 Foundation. This information will be useful for the implementation of more rational therapeutic
109 and preventive strategies against pneumococcus in Southwestern Colombia, where the therapy
110 for pneumococcal disease remains empirical due to the lack of rapid, sensitive and specific
111 diagnostic tests.

112 **2. Methodology:**

113 **2.1. Research Context, Population Definition and Inclusion Criteria**

114 This work consisted on a cross-sectional study conducted for the southwestern region of
115 Colombia (Figure 1), where 452 children under 5 years of age were randomly selected and
116 prospectively involved in the surveillance in 2019. For convenience and logistical support, all
117 children under five years of age eligible to participate in the study were those who attended the

118 Club Noel Children's Clinical Foundation of Cali (the main populated center of the Colombian
119 southwest) and who were evaluated by external consult for pediatric control visits (34–37). The
120 Club Noel Children's Clinical Foundation is a second level pediatric hospital that operates every
121 day of the year, serving up to 300 patients per day. Routine functions of the outpatient
122 department include monitoring of children's growth, immunization, nutritional counseling and
123 management of ailments. Although the population attending in Club Noel Children's Clinical
124 Foundation comes mainly from the city of Cali, another large number of pediatric patients come
125 from other nearby municipalities and departments, causing the study population to become a
126 mixture of people from different races, and representatives of both urban and rural areas.

127 **2.2. Sampling of the Study Population and Exclusion Criteria**

128 The study population of this work was constituted by the pneumococcal colonizing isolates from
129 the 452 children below 5 years old from the southwest Colombia involved in the investigation.
130 This sample size was estimated using the general formula for a proportion of a single population
131 with the following assumptions: 1) A total population of children under 5 years of age in the
132 Colombian southwest of 734,372 (according to DANE projections as of June 30, 2018, the total
133 population of the Colombian southwest would correspond to about 16% of the total national
134 territory (7,981,162 of 49,879,349), of which about 669,400 would be children under 5 years of
135 age) (38,39); 2) A prevalence rate of nasopharyngeal colonization by pneumococci of 50%
136 (according to unpublished studies by our research group in the city of Medellin: 55.5%); 3) A
137 95% confidence level; AND 4) A marginal error or possible loss of information of 20%. The
138 study participants were randomly associated and involved prospectively until the sample size
139 was completed. The main exclusion criteria were: 1) Children under 5 years old with invasive
140 pneumococcal disease diagnosed or critically affected by other diseases such as
141 bronchopulmonary dysplasia, chronic immunodeficiency, cancer or any other acute, moderate

142 or severe illness; 2) Children who had received antibiotics in the previous month or who had
143 previously received any immunosuppressive medication such as prednisolone, cyclosporine,
144 methotrexate, cyclophosphamide, azathioprine, mycophenolate mofetil or 5-fluorouracil; and 3)
145 Those children whose parents or guardians were unwilling or unable to give their informed
146 consent freely and spontaneously.

147 **2.3. Collection of Clinical and Sociodemographic Information**

148 This minimum risk level study was reviewed and approved by the Bioethics Committee of the
149 Club Noel Children's Clinical Foundation in Cali - Colombia. Initially, the study was socialized
150 with parents or guardians of each child, who subsequently accepted the voluntary participation
151 of their children by signing a written informed consent. Each participant was assigned a code
152 and only the personnel involved in the investigation had confidential access to the information
153 in the individual records. Then, the sociodemographic and housing data of the children under
154 5 years of age participating in the study were collected through a standardized and previously
155 tested survey, applied to the parents or guardians of each child. The questionnaire of survey
156 was mainly made up of closed questions that inquired about the date of birth, age, gender, race,
157 conditions and socioeconomic status of the home, the constitution of the family nucleus, among
158 others. Likewise, data were collected on the clinical history of the participating children such as
159 nutritional status, breastfeeding, consumption of antibiotics and other medications, the history
160 of the diseases suffered, and immunization records grouped into the following categories: not
161 immunized, incomplete vaccination, vaccination in process (for children <1 year of age), and
162 complete vaccination (for children > 1 year of age).

163 **2.4. Nasopharyngeal Swab and Preservation of Biological Material**

164 Nasopharyngeal swab samples were collected from each child selected to participate in the
165 study using sterile flexible swabs (Copan, Brescia, Italy), according to standardized procedures.

166 In brief, the swab was introduced through a nostril to the nasopharynx, where it was turned 180
167 degrees, and then carefully removed. Each swab collected was immediately introduced into a
168 cryovial with 1 mL of STGG transport medium (skim milk solution - tryptone - glucose - glycerol)
169 (40,41), for preservation at -30°C in the Microbiology Laboratory of Club Noel Children's Clinical
170 Foundation. Samples collected each week were transported on dry ice to the Central Research
171 Laboratory of the School of Microbiology of the University of Antioquia in Medellín, Colombia.

172 **2.5 Isolation, Cultivation, Identification and Cryopreservation of Pneumococci**

173 To isolate and cultivate the pneumococcus after arrival of the material to the laboratory, a 10
174 µL aliquot of the sample was used for growth in tryptic soy agar (TSA) solid medium,
175 supplemented with defibrinated sheep blood (5%), yeast extract (0.5%) and gentamicin (5
176 µg/mL). Pneumococci were incubated at 37°C and CO₂ (5%) for a maximum of 24 hours, after
177 which the following tests and assays were necessary to confirm their identification: 1) Evidence
178 of Hemolysis (although the pneumococci are catalase-negative bacteria, as α-hemolytic
179 microorganisms they can cause partial hemolysis due to the oxidation of iron in hemoglobin,
180 which causes greenish colonies to occur when grown on blood agar plates), 2) Gram staining
181 (pneumococci are Gram-positive), 3) Optochin sensitivity test (unlike other streptococci and α-
182 hemolytic microorganisms, pneumococci are sensitive to 5 mg ethylhydrocupreine
183 hydrochloride / optochin. Isolates with an inhibition zone ≥14 mm in diameter were considered
184 susceptible to optochin), and 4) Bile solubility test (the pneumococcus is soluble in bile). The
185 addition of small amounts of bile salts (2% sodium deoxycholate) results in complete
186 destruction of the pneumococcus after a short incubation period. Finally, stocks were generated
187 for the storage of the isolates, through the use of Todd-Hewitt supplemented with yeast extract
188 (THY) liquid culture medium, supplemented with glycerol (25%) in cryovials, which were then
189 preserved in an ultra-freezer at -80°C (2,41).

190 **2.6. Determination of Susceptibility / Antibiotic Resistance (VITEK-2 System)**

191 To test the susceptibility or resistance of the colonizing isolates against different antibiotics,
192 fresh cultures of *S. pneumoniae* were made on Mueller-Hinton Agar plates, supplemented with
193 Ram's Blood (5%) and incubated for 14 hours at 37°C and CO₂ (5%). The diluted inoculum was
194 then prepared in sterile 0.45% saline solution by resuspending the colonies until a turbid
195 suspension equivalent to that of a McFarland 0.5 standard was obtained. Subsequently,
196 following the protocols established by the Clinical and Laboratory Standards Institute (42,43),
197 the identification tests (GP Test Cards for Gram-positive cocci) and antimicrobial sensitivity
198 (AST03 Cards for Streptococcal Susceptibility) were performed, using the VITEK system -2
199 from BioMérieux. In short, the AST03 cards were inoculated, filled and inserted into the VITEK-
200 2 incubator reader device within 15 minutes after the preparation of the inoculum, according to
201 the manufacturer's instructions. The AST03 susceptibility cards of the VITEK-2 system contain
202 Wilkins-Chalgren culture medium, modified with the following antimicrobial agents: Benzyl-
203 penicillin (Meningitis, Oral and Pneumonia), Ceftriaxone (Meningitis and Other), Cefotaxime
204 (Meningitis and Other), Vancomycin, Erythromycin, Tetracycline, Clindamycin,
205 Chloramphenicol, Linezolid, Tigecycline, Trimethoprim / Sulfamethoxazole, Levofloxacin,
206 Moxifloxacin, Rifampicin. The strain ATCC 49619 was used as a pneumococcal control.
207 According to the CLSI criteria, colonizing pneumococcal isolates were classified as sensitive,
208 sensitive intermediate or resistant, according to established cut-off points (2,42,43).

209 **2.7. Statistical Analysis**

210 The statistical analysis of the data and results obtained in this study was performed as follows:
211 1) The data were tabulated, validated and analyzed using the Excel® program and the
212 Statistical Package for Social Sciences (SPSS®) version 20.0 (IBM Corporation, Chicago, IL,
213 USA); 2) Descriptive statistics (Univariate Analysis) were performed to summarize the

214 sociodemographic information, the proportions of nasopharyngeal carriage, the molecular
215 characteristics and susceptibility / antimicrobial resistance of the isolates; 3) Fisher and Chi-
216 square exact tests (Bivariate Analysis) were carried out to identify the candidate variables for
217 the multivariate analysis (Hosmer-Lemeshow Criteria, Cut Point $P < 0.25$); and finally, 4) a
218 logistic regression model (Multivariate Analysis) was made, using the Enter method, in order to
219 identify possible factors associated with the nasopharyngeal carriage of pneumococci. P values
220 < 0.05 were considered statistically significant.

221 **3. Results:**

222 **3.1. Socio-Demographic, Clinical, Housing and Life Habits Characteristics**

223 A total of 452 individuals under 5 years old of southwestern Colombia, who attended the Club
224 Noel Children's Clinic for outpatient services between September and October of 2019, were
225 included in this study. From this population, 241 (53.3%) were male and 211 (46.7%) were
226 female. According to the age, 105 (23.2%) children were under 1 year old, 85 (18.8%) were
227 one year old, 88 (19.5%) children were two years old, 77 (17.0%) were three years old, 69 (15.3
228 %) four years, and 28 (6.2%) five years old. The average age of the children was 30 months
229 with a standard deviation of 18 months. Regarding race or ethnicity, 349 (77.2%) identified
230 themselves as mestizo-Colombians, 68 (15.1%) declared themselves to be Afro-Colombians,
231 and 35 (7.7%) recognized themselves as indigenous people belonging to Amerindian
232 communities settled mainly in the department from Cauca. The majority of children 429 (94.5%)
233 belonged to socioeconomic strata 1, 2 and 3 (Low/medium-income levels), while two (0.4%)
234 participants belonged to stratum 6 (high-income level) from the municipalities of Yumbo and
235 Jamundí. Three hundred ninety-nine (88.3%) participating children came from 21 different
236 municipalities in the department of Valle del Cauca of which 244 (61.1%) lived in the city of
237 Cali. Participation of 51 (11.3%) children was obtained from the department of Cauca, while

238 from the department of Nariño no children could be included during the sampling period (Table
239 1A).

240 Forty-two (9.3%) participating children were clinically diagnosed with severe diseases such as
241 anemia, cerebral paralysis and hip dysplasia, among others. At some point in their life, 174
242 (38.5%) children were diagnosed with a respiratory illness such as pneumonia, asthma,
243 bronchitis, otitis and rhinitis, among others. However, they were fully recovered at the time of
244 sampling. On the other hand, 267 (59.1%) participants were diagnosed with respiratory signs
245 and symptoms at the time the samples were collected, such as nasal secretion, cough,
246 sneezing and phlegm, among others. Regarding the immunization status, 298 (65.9%)
247 participants had received at least one dose of pneumococcal vaccine, mainly from the biological
248 10-valent conjugate (99.7%). Only 187 (41.4%) participants certified to have a complete PCV
249 immunization schedule (2+1 doses) (Table 1B).

250 Regarding the conditions of housing, home and life habits, 51 (11.3%) children participating in
251 the study lived in overcrowded conditions (3 or more people per bedroom), while 98 (21.7%)
252 children had their own room and slept without companions in their own bed. Finally, 61 (13.5%)
253 participants lived with people who smoke cigarettes regularly, while 178 (39.4%) of the children
254 attended child care institutions near their homes (Table 1C).

255 **3.2. Nasopharyngeal carriage of *S. pneumoniae* in Children of the Colombian Southwest**

256 Of the 452 children examined, 189 (41.8%) were carriers of *S. pneumoniae*. The highest
257 proportion of nasopharyngeal colonization of *S. pneumoniae* was observed in two-year-old
258 children (41 children, 46.6%). The overall proportion of nasopharyngeal carriage of
259 *S. pneumoniae* was 105 (43.6%) in males versus 84 (39.8%) in females. Children belonging to
260 Indigenous communities had the highest proportion of nasopharyngeal colonization (22
261 children, 62.9%), while the lowest proportion was observed in Afro-Colombian participants (24

262 children, 35.3%). In children with the lowest socioeconomic condition (Stratum 1), the overall
263 proportion of nasopharyngeal carriage of *S. pneumoniae* was 63 (47.7%). The colonization rate
264 of children from the department of the Cauca was 58.8% (Table 2A).

265 Having been clinically diagnosed with severe diseases (23, 54.8%), respiratory diseases at
266 some time in life (79, 45.4%), and respiratory signs and symptoms at the time of sampling (133,
267 49.8%) were the variables identified with higher proportions of nasopharyngeal colonization by
268 *S. pneumoniae* than in healthy participants. Likewise, the colonization ratios of children not
269 immunized (71, 46.1%) or with incomplete immunization schedules (53, 47.7%) were higher
270 than those children with complete immunization schedule (65, 34.8%) (Table 2B, Figure 1).

271 The proportion of nasopharyngeal colonization of *S. pneumoniae* was 24 (47.1%) among
272 participants living in overcrowded conditions versus 41 (41.8%) in children who do not share
273 their room and sleeping alone in their bed. Of the participants living with people smoking
274 regularly at home, 23 (37.7%) were positive for *S. pneumoniae*. Finally, the proportion of
275 colonization of children attending child care institutions in the vicinity of their homes (87, 48.9%)
276 was higher than that of participants not attending any institution (102, 37.2%) (Table 2C).

277 **3.3. Analysis of the Factors Associated with the Nasopharyngeal Carriage of** 278 ***S. pneumoniae***

279 The results showed a correlation between pneumococcal colonization and the 2-year age group
280 (OR = 3.0; 95% CI = 1.0-8.3; $p = 0.041$). The nasopharyngeal carriage of *S. pneumoniae* was
281 significantly higher in children belonging to indigenous communities (OR = 2.7; 95% CI = 1.2-
282 5.9; $p = 0.014$). In addition, there was a significant association between nasopharyngeal
283 colonization of *S. pneumoniae* and nasal secretion at the time of sampling (OR = 2.1; 95% CI
284 = 1.3-3.3; $p = 0.003$). Failure to complete immunization schedules (OR = 2.5; 95% CI = 1.3-5.0;
285 $p = 0.008$) and not having received immunization against pneumococcus (OR = 1.7; 95% CI =

286 1.1-2.8; $p = 0.028$) was significantly associated with the presence of *S. pneumoniae* in the
287 nasopharynx in southwestern Colombia (Figure 2). Likewise, attending childcare institutions
288 (OR = 1.8; 95% CI = 1.0-3.2; $p = 0.042$) was significantly correlated with nasopharyngeal
289 colonization of *S. pneumoniae*. However, there was no significant association between gender,
290 socioeconomic stratum, severe diseases, respiratory disease at some time in life (asthma,
291 pneumonia, rhinitis, etc.), respiratory signs and symptoms at the time of sample collection
292 (cough, sneezing and phlegm, among others), low weight at birth, and overcrowding with the
293 nasopharyngeal carriage of *S. pneumoniae* (Table 3).

294 **3.4. Antimicrobial Resistance / Susceptibility Profiles of Colonizing Isolations**

295 The resistance / susceptibility profiles to the 18 antibiotics contained in the AST-03 card (VITEK-
296 2) of the *S. pneumoniae* colonizing isolates identified in this study are reported in Table 4. All
297 pneumococcal isolates were susceptible to vancomycin, chloramphenicol, linezolid, tigecycline,
298 levofloxacin, moxifloxacin and rifampicin. Fifty-five (29.1%) *S. pneumoniae* colonizing isolates
299 were susceptible to all antibiotics tested, 31 (16.4%) were resistant to an antimicrobial agent,
300 and 26 (13.8%) were resistant to two. Sixty-nine (36.5%) colonizing isolates of *S. pneumoniae*
301 were resistant to between three and ten different antibiotics (MDR: Multi-Drug Resistant), while
302 23 (12.2%) presented resistance profiles to at least one antibiotic in each class of antimicrobial
303 agents (XDR: Extensively-Drug Resistant). 109 (57.7%) *S. pneumoniae* clinical isolates not
304 susceptible to benzyl-penicillin (cut meningitis) were identified and isolated, and 86 (45.5%)
305 presented a reduced or intermediate susceptibility to this antibiotic, according to the oral cutoff
306 threshold. Seventy-seven (40.7%) colonizing isolates of *S. pneumoniae* were resistant to
307 erythromycin, 68 (36.0%) were resistant to tetracycline, 47 (24.9%) were resistant to
308 trimethoprim / sulfamethoxazole, and 46 (24.3%) were resistant to clindamycin. Regarding
309 Ceftriaxone and Cefotaxime (third generation cephalosporin), 51 (27.0%) and 41 (21.7%)

310 isolates of *S. pneumoniae* were identified with resistance profiles and intermediate
311 susceptibility, respectively.

312 **Discussion:**

313 In this study, a nasopharyngeal carriage rate of *S. pneumoniae* in children under 5 years of
314 41.8% was observed for the first time in Colombia. These results are in accordance with the
315 high frequencies of colonization observed by our research group in other cities of the country,
316 such as Medellín, where it has been possible to observe a colonization of 55.5% (unpublished
317 data). Other surveillance studies conducted in other countries have reported similar carriage
318 rates (17,35,37,44). This may, nevertheless, suggest that the Colombian southwest has a large
319 number of children belonging to low socioeconomic strata, carriers of *S. pneumoniae*, with a
320 high risk of developing invasive and non-invasive pneumococcal diseases. Consequently, they
321 represent a transmission reservoir, not only for members of their families (other children and
322 older adults), but also for their childhood partners with whom they interact in the community,
323 especially in institutions where care is provided (45). In our study, children belonging to the age
324 group of 2 years were identified with highest carriage rate (41: 46.6%), which coincides with
325 the times when parents begin their children's schooling in this region of the country. Likewise,
326 participants who said they belonged to indigenous communities were the most vulnerable to
327 the nasopharyngeal presence of *S. pneumoniae* (22: 62.9%), which also contributed to a
328 colonization rate well above the average for the department of Cauca (30: 58.8%). These
329 results coincide with reports from countries with similar conditions to those in this Latin
330 American region (23,46-50). However, in children 3, 4 and 5 years of age, a non-significant
331 decrease in the proportion of colonization by *S. pneumoniae* was observed, which could be the
332 reflection of the gradual acquisition of mucosal immunity from the respiratory tract superior,
333 especially in children with complete conjugate immunization schemes against pneumococcus,

334 and reduced exposure to the pathogen in nurseries and their homes. These findings confirm
335 that children under 2 years of age have a higher risk of acquiring *S. pneumoniae* and suffering
336 from their diseases, compared to the older age groups (3, 4 and 5 years).

337 Various studies worldwide have described several sociodemographic characteristics
338 associated with an increase in nasopharyngeal carrying of *S. pneumoniae*, which includes low
339 birth weight, overcrowding, sleeping with parents or other family members, and the fact of living
340 with people who smoke regularly (15). However, in our study, none of these factors was
341 associated with nasopharyngeal colonization of *S. pneumoniae*. On the contrary, other factors
342 such as environmental and / or host factors (underlying diseases, immunosuppression, etc.)
343 could be the main determinants of the distribution of the carriage among the children of the
344 Colombian southwest participating in this study. In addition to age and ethnicity, in the logistic
345 regression analysis, colonization rates for *S. pneumoniae* were significantly associated with
346 nasal secretion at the time of sampling, and with not being immunized against pneumococcus
347 or having the incomplete immunization schedule (2 + 1) (Figure 2) (3,18). Regarding the
348 environmental factor, children attending childcare institutions showed a significantly greater
349 nasopharyngeal colonization of *S. pneumoniae* compared to children who were not in school.
350 These results are similar to those found by our research group in children attending school in
351 the city of Medellín and to reports from countries with similar conditions (51–53). This finding is
352 of great relevance because exposure to other children during childhood, especially peers in
353 community care institutions, has been clearly associated with an increased risk of colonization
354 and invasive and non-invasive pneumococcal disease.

355 The results of the susceptibility study revealed higher antibiotic resistance of *S. pneumoniae* to
356 relatively cheap and readily available antibiotics for the population such as benzyl-penicillin cut
357 meningitis (57.7%), erythromycin (40.7%), tetracycline (36.0%) and

358 trimethoprim/sulfamethoxazole (24.9%), and more expensive but of variable use alternatives
359 such as ceftriaxone (27.0%) and clindamycin (24.3%). This observation is consistent with
360 previous reports in Venezuela and other countries of the world (33,54-58). On the other hand,
361 vancomycin, chloramphenicol, linezolid, tigecycline, levofloxacin, moxifloxacin and rifampicin
362 were the most effective antibiotics against *S. pneumoniae* isolates, all with 100% antimicrobial
363 susceptibility, which is consistent with reports from other countries of the region (30,33,59).
364 Twenty-three (12.2%) colonizing isolates of *S. pneumoniae* presented resistance profiles to at
365 least one antibiotic in each class of antimicrobial agents, which includes them in the dangerous
366 group of extensively drug-resistant pneumococci (XDR). Likewise, 69 (36.5%) isolates were
367 resistant to between three and ten different antibiotics, being considered in this study as multi-
368 drug resistant *S. pneumoniae* (MDR). Less than 1/3 of the pneumococci isolated in
369 southwestern Colombia were susceptible to all antibiotics tested, which is a direct product of
370 frequent and inappropriate use of the chemotherapeutics. Although data on the use of different
371 antibiotics in low- and middle-income countries are underrepresented, the rates of resistance
372 of pneumococci to antimicrobial agents vary according to geographic region and the different
373 population subgroups analyzed (31,34,60). These variations represent major challenges for
374 health systems in Latin American countries and reflect the uncontrolled and low-cost availability
375 of some of these medical resources (30). This phenomenon is not foreign to Colombia and its
376 southwestern region (14.61–63), which would be exerting greater selection pressure for
377 resistant *S. pneumoniae* strains, favoring the increase in their frequency and, therefore,
378 decreasing the efficacy of these antibiotics in the treatment of *S. pneumoniae* affected patients.

379 **Conclusions:**

380 In this study, a general proportion of nasopharyngeal colonization of *S. pneumoniae* of 41.8%
381 is reported for the southwestern region of Colombia, with a higher frequency among 2-year-old

382 participants. Belonging to Native American (indigenous) communities, not being immunized
383 against pneumococcus, not completing established immunization schemes, attending
384 child-care institutions, and presenting nasal secretion are risk factors for nasopharyngeal
385 carrying of *S. pneumoniae* in this region of the country. On the other hand, a non-susceptibility
386 of *S. pneumoniae* to benzyl-penicillin (meningitis and oral cuts), increased resistance to
387 antibiotics erythromycin, tetracycline, trimethoprim/sulfamethoxazole and clindamycin was
388 observed, in addition to resistance and intermediate levels of susceptibility to cephalosporin of
389 broad spectrum (ceftriaxone and cefotaxime). In conclusion, with this study the local and
390 regional frequency data of children under 5 years of age carrying *S. pneumoniae* is obtained
391 for the southwest of Colombia for the first time. This high proportion of children carrying
392 *S. pneumoniae* could show an important reservoir of bacterial transmission among children
393 under 5 years of age in that community, which could potentially lead to the onset of
394 pneumococcal diseases with serious consequences for the health of people in this Colombian
395 region. Therefore, there is a clear need to expand pneumococcal conjugate immunization in
396 the community and ensure compliance with established immunization schedules. Additionally,
397 the determination of the association of nasopharyngeal colonization of resistant MDR and XDR-
398 like strains with the development of invasive infection by resistant strains is important to
399 establish rational treatments for the alleged *S. pneumoniae* infections in southwestern
400 Colombia.

401 **Acknowledgements:**

402 The authors thank Jaime Dominguez Navia, Luz Myriam Claros, María Victoria Hernández,
403 María Victoria Muñoz, María del Palmar, Jhonny Castrillón, and all the staff of Club Noel
404 Children's Clinical Foundation, Cali, Colombia for facilitating the realization of this study.

405

406 **Authors' Contribution:**

407 Conceptualization: GG, JPR, LFM, JCO, LJA, JAB, AGM, JLM, SH.

408 Data curation: GG, JPR, SC, MAP, JLT, LMM, LFV, YAZ, JLM.

409 Formal analysis: GG, JPR, JLM, SH.

410 Funding acquisition: GG.

411 Investigation: GG, JPR, SC, JDC, MAP, LFM, JLT, JCO, LMM, JCR, LFV, AMF, YAZ, MEC,
412 LJA, AJM, JAB, AGM, SH.

413 Methodology: GG, JPR, SC, JDC, MAP, LFM, JLT, JCO, LMM, JCR, LFV, AMF, YAZ, MEC,
414 LJA, AJM, JAB, AGM, SH.

415 Project administration: GG.

416 Resources: GG.

417 Software: Not applicable.

418 Supervision: GG, JPR, SH.

419 Validation: GG, JLM.

420 Visualization: GG, JLM.

421 Writing - original draft: GG, AGM, JLM.

422 Writing - review & editing: GG, JPR, SC, JDC, MAP, LFM, JLT, JCO, LMM, JCR, LFV, AMF,
423 YAZ, MEC, LJA, AJM, JAB, AGM, JLM, SH.

424 **Conflict of Interest:**

425 Resources for the experimental development of this research were provided by Pfizer, Inc.,
426 through the Grant: IIR WI244770.

427 **References:**

- 428 1. Brown, J., Hammerschmidt, S., and Orihuela, C., 2015. *Streptococcus pneumoniae*:
429 Molecular Mechanisms of Host-Pathogen Interactions. ELSEVIER.
430 [https://www.elsevier.com/books/streptococcus pneumoniae/brown/978-0-12-410530-0](https://www.elsevier.com/books/streptococcus-pneumoniae/brown/978-0-12-410530-0)
- 431 2. WHO. 2003. Manual for the laboratory identification and antimicrobial susceptibility testing
432 of bacterial pathogens of public health concern in the developing world.
433 [https://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_RMD_2003_](https://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_RMD_2003_6/en/)
434 [6/en/](https://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_RMD_2003_6/en/)
- 435 3. Walker CLF, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of
436 childhood pneumonia and diarrhoea. *Lancet Lond Engl.* 20 de abril de
437 2013;381(9875):1405-16.
- 438 4. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional,
439 and national morbidity, mortality, and aetiologies of lower respiratory infections in 195
440 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
441 *Lancet Infect Dis.* 2018;18(11):1191-210.
- 442 5. Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E, Hoet B, et al. Carriage of
443 *Streptococcus pneumoniae* and other respiratory bacterial pathogens in low and lower-
444 middle income countries: a systematic review and meta-analysis. *PloS One.*
445 2014;9(8):e103293.
- 446 6. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional,
447 and national causes of child mortality in 2008: a systematic analysis. *Lancet Lond Engl.* 5
448 de junio de 2010;375(9730):1969-87.

- 449 7. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of
450 disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global
451 estimates. *The Lancet*. 12 de septiembre de 2009;374(9693):893-902.
- 452 8. Valenzuela MT, O'Loughlin R, De La Hoz F, Gomez E, Constenla D, Sinha A, et al. The
453 burden of pneumococcal disease among Latin American and Caribbean children: review of
454 the evidence. *Rev Panam Salud Publica Pan Am J Public Health*. marzo de
455 2009;25(3):270-9.
- 456 9. Zar HJ, Madhi SA. Childhood pneumonia--progress and challenges. *South Afr Med J Suid-
457 Afr Tydskr Vir Geneesk*. septiembre de 2006;96(9 Pt 2):890-900.
- 458 10. Falade AG, Ayede AI. Epidemiology, aetiology and management of childhood acute
459 community-acquired pneumonia in developing countries--a review. *Afr J Med Med Sci*.
460 diciembre de 2011;40(4):293-308.
- 461 11. Rodríguez L, Cervantes E, Ortiz R. Malnutrition and gastrointestinal and respiratory
462 infections in children: a public health problem. *Int J Environ Res Public Health*.
463 2011;8(4):1174-205.
- 464 12. Martínez-Vernaza S, Mckinley E, Soto MJ, Gualtero S. Neumonía adquirida en la
465 comunidad: una revisión narrativa. *Univ Medica*. diciembre de 2018;59(4):93-102.
- 466 13. Castañeda-Orjuela C, Alvis-Guzmán N, de la Hoz-Restrepo F. Impacto de la enfermedad
467 por *Streptococcus pneumoniae* en población adulta mayor en Bogotá, Colombia, 2008.
468 *Rev Salud Pública*. febrero de 2010;12(1):38-50.
- 469 14. Salud, I.N.d., Publicaciones Informes y boletines de vigilancia por laboratorio. Informe
470 Nacional de SIREVA II - Colombia 2006-2018. SIREVA II, 2019: p. 16.
471 [http://www.ins.gov.co/buscador-eventos/Paginas/Informes-y-boletines-de-vigilancia-por-](http://www.ins.gov.co/buscador-eventos/Paginas/Informes-y-boletines-de-vigilancia-por-laboratorio-micro.aspx#InplviewHash6c8e35e2-66db-4a75-8f06-)
472 [laboratorio-micro.aspx#InplviewHash6c8e35e2-66db-4a75-8f06-](http://www.ins.gov.co/buscador-eventos/Paginas/Informes-y-boletines-de-vigilancia-por-laboratorio-micro.aspx#InplviewHash6c8e35e2-66db-4a75-8f06-)

- 473 fb3c6e13971f=WebPartID%3D%7B6C8E35E2--66DB--4A75--8F06--
474 FB3C6E13971F%7D-FilterField1%3DLaboratorio-
475 FilterValue1%3DMicrobiolog%25C3%25ADa
- 476 15. Bogaert D, De Groot R, Hermans PWM. *Streptococcus pneumoniae* colonisation: the key
477 to pneumococcal disease. Lancet Infect Dis. marzo de 2004;4(3):144-54.
- 478 16. Cardozo DM, Nascimento-Carvalho CMC, Souza FR, Silva NMS. Nasopharyngeal
479 colonization and penicillin resistance among pneumococcal strains: a worldwide 2004
480 update. Braz J Infect Dis Off Publ Braz Soc Infect Dis. agosto de 2006;10(4):293-304.
- 481 17. Jourdain S, Smeesters PR, Denis O, Dramaix M, Sputael V, Malaviolle X, et al. Differences
482 in nasopharyngeal bacterial carriage in preschool children from different socioeconomic
483 origins. Clin Microbiol Infect. 1 de junio de 2011;17(6):907-14.
- 484 18. Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O'Brien KL, et al. The fundamental
485 link between pneumococcal carriage and disease. Expert Rev Vaccines. julio de
486 2012;11(7):841-55.
- 487 19. Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rümke HC, et al.
488 Colonisation by *Streptococcus pneumoniae* and *Staphylococcus aureus* in healthy
489 children. Lancet Lond Engl. 5 de junio de 2004;363(9424):1871-2.
- 490 20. Garcia-Rodriguez JA. Dynamics of nasopharyngeal colonization by potential respiratory
491 pathogens. J Antimicrob Chemother. 1 de diciembre de 2002;50(90003):59-74.
- 492 21. Jounio U, Juvonen R, Bloigu A, Silvennoinen-Kassinen S, Kaijalainen T, Kauma H, et al.
493 Pneumococcal carriage is more common in asthmatic than in non-asthmatic young men.
494 Clin Respir J. octubre de 2010;4(4):222-9.
- 495 22. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships
496 between invasive and carriage *Streptococcus pneumoniae* and serotype- and clone-

- 497 specific differences in invasive disease potential. *J Infect Dis.* 1 de mayo de
498 2003;187(9):1424-32.
- 499 23. Mackenzie GA, Leach AJ, Carapetis JR, Fisher J, Morris PS. Epidemiology of
500 nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-
501 sectional surveys in a population with high rates of pneumococcal disease. *BMC Infect Dis.*
502 23 de octubre de 2010;10:304.
- 503 24. Faden H, Duffy L, Wasielewski R, Wolf J, Krystofik D, Tung Y, et al. Relationship between
504 Nasopharyngeal Colonization and the Development of Otitis Media in Children. *J Infect Dis.*
505 junio de 1997;175(6):1440-5.
- 506 25. Dunne EM, Murad C, Sudigdoadi S, Fadlyana E, Tarigan R, Indriyani SAK, et al. Carriage
507 of *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and
508 *Staphylococcus aureus* in Indonesian children: A cross-sectional study. *PLoS One.*
509 2018;13(4):e0195098.
- 510 26. Gamez G, Hammerschmidt S. Combat pneumococcal infections: adhesins as candidates
511 for protein-based vaccine development. *Curr Drug Targets.* marzo de 2012;13(3):323-37.
- 512 27. WHO. Pneumococcal Vaccines World Health Organization Position Paper. *Wkly Epidemiol*
513 *Rec* 2003; 78:97e120.
514 http://www.who.int/immunization/policy/position_papers/pneumococcus/en/
- 515 28. Friedland IR, McCracken GH. Management of Infections Caused by Antibiotic-Resistant
516 *Streptococcus pneumoniae*. *N Engl J Med.* 11 de agosto de 1994;331(6):377-82.
- 517 29. Quintero B, Araque M, van der Gaast-de Jongh C, Escalona F, Correa M, Morillo-Puente
518 S, et al. Epidemiology of *Streptococcus pneumoniae* and *Staphylococcus aureus*
519 colonization in healthy Venezuelan children. *Eur J Clin Microbiol Infect Dis Off Publ Eur*
520 *Soc Clin Microbiol.* enero de 2011;30(1):7-19.

- 521 30. Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American
522 countries, 1997-2007. *Rev Panam Salud Publica Pan Am J Public Health.* marzo de
523 2010;27(3):219-25.
- 524 31. Zanichelli V, Monnier AA, Gyssens IC, Adriaenssens N, Versporten A, Pulcini C, et al.
525 Variation in antibiotic use among and within different settings: a systematic review. *J*
526 *Antimicrob Chemother.* 01 de 2018;73(suppl_6):vi17-29.
- 527 32. Inverarity D, Diggle M, Ure R, Johnson P, Altstadt P, Mitchell T, et al. Molecular
528 epidemiology and genetic diversity of pneumococcal carriage among children in Beni State,
529 Bolivia. *Trans R Soc Trop Med Hyg.* agosto de 2011;105(8):445-51.
- 530 33. Quintero B, Araque M. [Serotype profile and antibiotyping of *Streptococcus pneumoniae*
531 strains isolated from nasal carriage in pediatric patients]. *Invest Clin.* marzo de
532 2006;47(1):17-26.
- 533 34. Abaye G, Fekadu H, Haji K, Alemu D, Anjulo AA, Yadate DT. Prevalence and risk factors
534 of pneumococcal nasopharyngeal carriage in healthy children attending kindergarten, in
535 district of Arsi Zone, South East, Ethiopia. *BMC Res Notes.* diciembre de 2019;12(1):253.
- 536 35. Assefa A, Gelaw B, Shiferaw Y, Tigabu Z. Nasopharyngeal Carriage and Antimicrobial
537 Susceptibility Pattern of *Streptococcus pneumoniae* among Pediatric Outpatients at
538 Gondar University Hospital, North West Ethiopia. *Pediatr Neonatol.* 1 de octubre de
539 2013;54(5):315-21.
- 540 36. Gebre T, Tadesse M, Aragaw D, Feye D, Beyene HB, Seyoum D, et al. Nasopharyngeal
541 Carriage and Antimicrobial Susceptibility Patterns of *Streptococcus pneumoniae* among
542 Children under Five in Southwest Ethiopia. *Child Basel Switz.* 19 de abril de 2017;4(4).
- 543 37. Hernandez-Bou S, Garcia-Garcia JJ, Gene A, Esteva C, del Amo E, Muñoz-Almagro C.
544 Pneumococcal carriage in children attending a hospital outpatient clinic in the era of


- 545 pneumococcal conjugate vaccines in Barcelona. *Diagn Microbiol Infect Dis*. noviembre de
546 2012;74(3):258-62.
- 547 38. DANE, Colombia. 2018. Demografía y población.
548 <https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion>.
- 549 39. Víadata - Centro Nacional de Consultoría, Colombia. 2019.
550 <https://www.centronacionaldeconsultoria.com/viadata>
- 551 40. O'Brien KL, Bronsdon MA, Dagan R, Yagupsky P, Janco J, Elliott J, et al. Evaluation of a
552 medium (STGG) for transport and optimal recovery of *Streptococcus pneumoniae* from
553 nasopharyngeal secretions collected during field studies. *J Clin Microbiol*. marzo de
554 2001;39(3):1021-4.
- 555 41. Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, et al. Standard
556 method for detecting upper respiratory carriage of *Streptococcus pneumoniae*: Updated
557 recommendations from the World Health Organization Pneumococcal Carriage Working
558 Group. *Vaccine*. 17 de diciembre de 2013;32(1):165-79.
- 559 42. Ligozzi M, Bernini C, Bonora MG, De Fatima M, Zuliani J, Fontana R. Evaluation of the
560 VITEK 2 system for identification and antimicrobial susceptibility testing of medically
561 relevant gram-positive cocci. *J Clin Microbiol*. mayo de 2002;40(5):1681-6.
- 562 43. CLSI. Performance standards for antimicrobial susceptibility testing; 29th Ed. CLSI
563 supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
- 564 44. Ercibengoa M, Arostegi N, Marimón JM, Alonso M, Pérez-Trallero E. Dynamics of
565 pneumococcal nasopharyngeal carriage in healthy children attending a day care center in
566 northern Spain. Influence of detection techniques on the results. *BMC Infect Dis*. 22 de
567 marzo de 2012;12:69.

- 568 45. Navne JE, Børresen ML, Slotved HC, Andersson M, Melbye M, Ladefoged K, et al.
569 Nasopharyngeal bacterial carriage in young children in Greenland: a population at high risk
570 of respiratory infections. *Epidemiol Infect.* 2016;144(15):3226-36.
- 571 46. Abdullahi O, Nyiro J, Lewa P, Slack M, Scott JAG. The Descriptive Epidemiology of
572 *Streptococcus pneumoniae* and *Haemophilus influenzae* Nasopharyngeal Carriage in
573 Children and Adults in Kilifi District, Kenya: *Pediatr Infect Dis J.* enero de 2008;27(1):59-
574 64.
- 575 47. Neves FPG, Pinto TCA, Corrêa MA, dos Anjos Barreto R, de Souza Gouveia Moreira L,
576 Rodrigues HG, et al. Nasopharyngeal carriage, serotype distribution and antimicrobial
577 resistance of *Streptococcus pneumoniae* among children from Brazil before the
578 introduction of the 10-valent conjugate vaccine. *BMC Infect Dis.* 13 de julio de 2013;13:318.
- 579 48. Otsuka T, Chang B, Shirai T, Iwaya A, Wada A, Yamanaka N, et al. Individual risk factors
580 associated with nasopharyngeal colonization with *Streptococcus pneumoniae* and
581 *Haemophilus influenzae*: a Japanese birth cohort study. *Pediatr Infect Dis J.* julio de
582 2013;32(7):709-14.
- 583 49. Usuf E, Bottomley C, Adegbola RA, Hall A. Pneumococcal carriage in sub-Saharan Africa-
584 -a systematic review. *PloS One.* 2014;9(1):e85001.
- 585 50. Vallès X, Flannery B, Roca A, Mandomando I, Sigaúque B, Sanz S, et al. Serotype
586 distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of
587 *Streptococcus pneumoniae* among children in rural Mozambique. *Trop Med Int Health.*
588 2006;11(3):358-66.
- 589 51. Espinosa-de Los Monteros LE, Jiménez-Rojas V, Aguilar-Ituarte F, Cashat-Cruz M, Reyes-
590 López A, Rodríguez-Suárez R, et al. *Streptococcus pneumoniae* isolates in healthy children

- 591 attending day-care centers in 12 states in Mexico. *Salud Publica Mex.* agosto de
592 2007;49(4):249-55.
- 593 52. Masuda K, Masuda R, Nishi J-I, Tokuda K, Yoshinaga M, Miyata K. Incidences of
594 nasopharyngeal colonization of respiratory bacterial pathogens in Japanese children
595 attending day-care centers. *Pediatr Int Off J Jpn Pediatr Soc.* agosto de 2002;44(4):376-
596 80.
- 597 53. Zemlicková H, Urbásková P, Adámková V, Motlová J, Lebedová V, Procházka B.
598 Characteristics of *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella*
599 *catarrhalis* and *Staphylococcus aureus* isolated from the nasopharynx of healthy children
600 attending day-care centres in the Czech Republic. *Epidemiol Infect.* diciembre de
601 2006;134(6):1179-87.
- 602 54. Birindwa AM, Emgård M, Nordén R, Samuelsson E, Geravandi S, Gonzales-Siles L, et al.
603 High rate of antibiotic resistance among pneumococci carried by healthy children in the
604 eastern part of the Democratic Republic of the Congo. *BMC Pediatr* [Internet]. 19 de
605 noviembre de 2018 [citado 23 de diciembre de 2019];18. Disponible en:
606 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241069/>
- 607 55. Emgård M, Msuya SE, Nyombi BM, Moshia D, Gonzales-Siles L, Nordén R, et al. Carriage
608 of penicillin-non-susceptible pneumococci among children in northern Tanzania in the 13-
609 valent pneumococcal vaccine era. *Int J Infect Dis.* 1 de abril de 2019;81:156-66.
- 610 56. Hill PC, Cheung YB, Akisanya A, Sankareh K, Lahai G, Greenwood BM, et al.
611 Nasopharyngeal carriage of *Streptococcus pneumoniae* in Gambian infants: a longitudinal
612 study. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 15 de marzo de 2008;46(6):807-14.

- 613 57. Hill PC, Akisanya A, Sankareh K, Cheung YB, Saaka M, Lahai G, et al. Nasopharyngeal
614 Carriage of *Streptococcus pneumoniae* in Gambian Villagers. Clin Infect Dis. 15 de
615 septiembre de 2006;43(6):673-9.
- 616 58. Stacevičienė I, Petraitiene S, Vaičiūnienė D, Alasevičius T, Kirslienė J, Usonis V. Antibiotic
617 resistance of *Streptococcus pneumoniae*, isolated from nasopharynx of preschool children
618 with acute respiratory tract infection in Lithuania. BMC Infect Dis. diciembre de
619 2016;16(1):216.
- 620 59. Gazi H, Kurutepe S, Sürücüoğlu S, Teker A, Ozbakkaloglu B. Antimicrobial susceptibility of
621 bacterial pathogens in the oropharynx of healthy school children in Turkey. Indian J Med
622 Res. noviembre de 2004;120(5):489-94.
- 623 60. Bayer M, Aslan G, Emekdaş G, Kuyucu N, Kanik A. [Nasopharyngeal carriage of
624 *Streptococcus pneumoniae* in healthy children and multidrug resistance]. Mikrobiyol Bul.
625 abril de 2008;42(2):223-30.
- 626 61. Cataño JC, Castaño O. Evaluación del impacto de un programa de vigilancia
627 epidemiológica del consumo de antibióticos y la flora en una clínica de tercer nivel. Infectio.
628 marzo de 2009;13(1):6-13.
- 629 62. José Pallares C, Martínez E. Implementación de un programa de uso regulado de
630 antibióticos en 2 unidades de cuidado intensivo medico-quirúrgico en un hospital
631 universitario de tercer nivel en Colombia. Infectio. 1 de enero de 2012;16(4):192-8.
- 632 63. Leal AL, Castañeda E. [Antimicrobial susceptibility of *Streptococcus pneumoniae*
633 colonizing the nasopharynx of Colombian children with pneumonia]. Rev Panam Salud
634 Publica Pan Am J Public Health. abril de 1997;1(4):266-72.
- 635

636 **Figure 1.** Geographic location of southwestern Colombia in the World. **A.** Republic of Colombia
637 in the world. **B.** Southwestern region in the Colombian territory. **C.** Departments of Valle del
638 Cauca, Cauca, Nariño and Putumayo and their capitals Cali, Popayán, Pasto and Mocoa,
639 respectively. Club Noel Children’s Clinical Foundation is located in Santiago de Cali (Valle del
640 Cauca). Bogotá is the capital of Colombia.



641

642 **Table 1.** Sociodemographic (A), clinics (B) and housing and lifestyle habits (C) characteristics
 643 of the 452 outpatient children of the Club Noel Children's Clinic, involved in the study, in
 644 the year 2019.

A. Sociodemographic Characteristics			
Variable		n	%
Gender	Male	241	53,3
	Female	211	46,7
Age in years	0	105	23,2
	1	85	18,8
	2	88	19,5
	3	77	17,0
	4	69	15,3
	5	28	6,2
Department	Valle del Cauca	399	88,3
	Cauca	2	0,4
	Nariño	0	0,0
	Putumayo	51	11,3
Race or Culture	Native	35	7,7
	Afro-Colombian	68	15,1
	Mestizo-Colombian	349	77,2
Socioeconomic Stratum	1	132	29,2
	2	184	40,7
	3	113	25,0
	4	16	3,5
	5	5	1,2
	6	2	0,4
B. Clinical Characteristics			
Variable		n	%
Severe Underlying Disease (Total)	Yes	42	9,3
	No	410	90,7
Previous Respiratory Diseases (Total)	Yes	174	38,5
	No	278	61,5
Previous Respiratory Disease (Asthma)	Yes	48	10,6
	No	404	89,4
Previous Respiratory Disease (Tonsillitis)	Yes	24	5,3
	No	428	94,7
Previous Respiratory Disease (Bronchitis)	Yes	39	8,6
	No	413	91,4
Previous Respiratory Disease (Laryngitis)	Yes	13	2,9
	No	439	97,1
Previous Respiratory Disease (Otitis)	Yes	37	8,2
	No	415	91,8
Previous Respiratory Disease (Rhinitis)	Yes	28	6,2
	No	424	93,8
Previous Respiratory Disease (Sinusitis)	Yes	22	4,9
	No	430	95,1
Previous Respiratory Disease (Pneumonia)	Yes	51	11,3

	No	401	88,7
Previous Respiratory Disease (Meningitis)	Yes	4	0,9
	No	448	99,1
Respiratory Signs and Symptoms (Total)	Yes	267	59,1
	No	185	40,9
Respiratory Signs and Symptoms (Fever)	Yes	33	7,3
	No	419	92,7
Respiratory Signs and Symptoms (Nasal Secretion)	Yes	169	37,4
	No	283	62,6
Respiratory Signs and Symptoms (Sneezing)	Yes	127	28,1
	No	325	71,9
Respiratory Signs and Symptoms (Cough)	Yes	166	36,7
	No	286	63,3
Respiratory Signs and Symptoms (Phlegm)	Yes	91	20,1
	No	361	79,9
Respiratory Signs and Symptoms (Difficulty Breathing)	Yes	20	4,4
	No	432	95,6
Respiratory Signs and Symptoms (Fatigue)	Yes	7	1,5
	No	445	98,5
Low Weight at Birth	Yes	101	22,3
	No	351	77,7
Vaccination Status	Non-Immunized	154	34,1
	Incomplete Immunization	36	8,0
	Immunization in Process	73	16,1
	Complete Immunization	187	41,8

C. Characteristics of the Living Quarters, Home and Life Habits

Variable		n	%
Overcrowding at Home	Yes	51	11,3
	No	401	88,7
Shared Bedroom	Yes	354	78,3
	No	98	21,7
Living with Smokers	Yes	61	13,5
	No	391	86,5
Contact With Sick Person(s) (Otitis)	Yes	18	4,0
	No	434	96,0
Contact With Sick Person(s) (Sinusitis)	Yes	22	4,9
	No	430	95,1
Contact With Sick Person(s) (Bronchitis)	Yes	7	1,5
	No	445	98,5
Contact With Sick Person(s) (Pneumonia)	Yes	5	1,1
	No	447	98,9
Contact With Sick Person(s) (Meningitis)	Yes	2	0,4
	No	450	99,6
Hospitalized Home Members	Yes	27	6,0
	No	425	94,0
Assists to Child Care Center	Yes	178	39,4
	No	274	60,6
Total		452	100

Table 2. Bivariate analysis of associated factors for *Streptococcus pneumoniae* nasopharyngeal colonization in 452 outpatient children of the Club Noel Children's Clinic, involved in the study, in 2019.

Variable		n	(%)	Colonization (n = 189)				p	OR Raw	(IC95%)
				No		Yes				
				n	(%)	n	(%)			
Gender	Male	24	(53,3)	13	(56,4)	10	(43,6)	0,419	1,2	(0,8 - 1,7)
	Female	21	(46,7)	12	(60,2)	84	(39,8)		1	
Age in Years	0	10	(23,2)	60	(57,1)	45	(42,9)	0,307	1,6	(0,7 - 3,8)
	1	85	(18,8)	54	(63,5)	31	(36,5)	0,678	1,2	(0,5 - 3,0)
	2	88	(19,5)	47	(53,4)	41	(46,6)	0,182	1,8	(0,8 - 4,5)
	3	77	(17)	42	(54,5)	35	(45,5)	0,224	1,8	(0,7 - 4,4)
	4	69	(15,3)	41	(59,4)	28	(40,6)	0,439	1,4	(0,6 - 3,6)
	5	28	(6,2)	19	(67,9)	9	(32,1)		1	
Department	Valle del Cauca	39	(88,3)	24	(60,4)	15	(39,6)	0,010	2,2	(1,2 - 3,9)
	Cauca	51	(11,3)	21	(41,2)	30	(58,8)	0,766	1,5	(0,1 - 24,6)
	Putumayo	2	(0,4)	1	(50)	1	(50)		1	
Race or Culture	Native	35	(7,7)	13	(37,1)	22	(62,9)	0,015	2,4	(1,2 - 5,0)
	Afro-Colombian	68	(15)	44	(64,7)	24	(35,3)	0,383	0,8	(0,5 - 1,3)
	Mestizo-Colombian	34	(77,2)	20	(59)	14	(41)		1	
Socioeconomic Stratum	1	13	(29,2)	69	(52,3)	63	(47,7)	0,060	2,6	(1,0 - 7,0)

2	18 4	(40,7)	11 0	(59,8)	74	(40,2)	0,19 5	1,9	(0,7 - 5,1)
3	11 3	(25)	67	(59,3)	46	(40,7)	0,19 4	1,9	(0,7 - 5,3)
4, 5 y 6	23	(5,1)	17	(73,9)	6	(26,1)		1	

B. Clinical Characteristics

Variable		n	(%)	Colonization (n = 189)				p	OR Raw	(IC95%)
				No		Yes				
				n	(%)	n	(%)			
Severe Underlying Disease (Total)	Yes	42	(9,3)	19	(45,2)	23	(54,8)	0,07 7	1,8	(0,9 - 3,4)
	No	41	(90,7)	24	(59,5)	16	(40,5)		1	
Previous Respiratory Disease (Total)	Yes	17	(38,5)	95	(54,6)	79	(45,4)	0,22 1	1,3	(0,9 - 1,9)
	No	27	(61,5)	16	(60,4)	11	(39,6)		1	
Previous Respiratory Disease (Asthma)	Yes	48	(10,6)	23	(47,9)	25	(52,1)	0,13 0	1,6	(0,9 - 2,9)
	No	40	(89,4)	24	(59,4)	16	(40,6)		1	
Previous Respiratory Disease (Tonsillitis)	Yes	24	(5,3)	15	(62,5)	9	(37,5)	0,66 0	0,8	(0,4 - 1,9)
	No	42	(94,7)	24	(57,9)	18	(42,1)		1	
Previous Respiratory Disease (Bronchitis)	Yes	39	(8,6)	24	(61,5)	15	(38,5)	0,65 7	0,9	(0,4 - 1,7)
	No	41	(91,4)	23	(57,9)	17	(42,1)		1	
Previous Respiratory Disease (Laryngitis)	Yes	13	(2,9)	8	(61,5)	5	(38,5)	0,80 4	0,9	(0,3 - 2,7)
	No	43	(97,1)	25	(58,1)	18	(41,9)		1	
Previous Respiratory Disease (Otitis)	Yes	37	(8,2)	23	(62,2)	14	(37,8)	0,60 9	0,8	(0,4 - 1,7)

	No	41 5	(91,8)	24 0	(57,8)	17 5	(42,2)		1	
Previous Respiratory Disease (Rhinitis)	Yes	28	(6,2)	10	(35,7)	18	(64,3)	0,01 6	2,7	(1,2 - 5,9)
	No	42 4	(93,8)	25 3	(59,7)	17 1	(40,3)		1	
Previous Respiratory Disease (Sinusitis)	Yes	22	(4,9)	12	(54,5)	10	(45,5)	0,72 3	1,2	(0,5 - 2,8)
	No	43 0	(95,1)	25 1	(58,4)	17 9	(41,6)		1	
Previous Respiratory Disease (Pneumonia)	Yes	51	(11,3)	28	(54,9)	23	(45,1)	0,61 4	1,2	(0,6 - 2,1)
	No	40 1	(88,7)	23 5	(58,6)	16 6	(41,4)		1	
Previous Respiratory Disease (Meningitis)	Yes	4	(0,9)	2	(50)	2	(50)	0,74 0	1,4	(0,2 - 10,0)
	No	44 8	(99,1)	26 1	(58,3)	18 7	(41,7)		1	
Respiratory Signs and Symptoms (Total)	Yes	26 7	(59,1)	13 4	(50,2)	13 3	(49,8)	0,00 0	2,3	(1,5 - 3,4)
	No	18 5	(40,9)	12 9	(69,7)	56	(30,3)		1	
Respiratory Signs and Symptoms (Fever)	Yes	33	(7,3)	19	(57,6)	14	(42,4)	0,94 1	1,0	(0,5 - 2,1)
	No	41 9	(92,7)	24 4	(58,2)	17 5	(41,8)		1	
Respiratory Signs and Symptoms (Nasal Secretion)	Yes	16 9	(37,4)	74	(43,8)	95	(56,2)	0,00 0	2,6	(1,7 - 3,8)
	No	28 3	(62,6)	18 9	(66,8)	94	(33,2)		1	
Respiratory Signs and Symptoms (Sneezing)	Yes	12 7	(28,1)	68	(53,5)	59	(46,5)	0,21 2	1,3	(0,9 - 2,0)
	No	32 5	(71,9)	19 5	(60)	13 0	(40)		1	
Respiratory Signs and Symptoms (Cough)	Yes	16 6	(36,7)	77	(46,4)	89	(53,6)	0,00 0	2,1	(1,5 - 3,2)
	No	28 6	(63,3)	18 6	(65)	10 0	(35)		1	

Respiratory Signs and Symptoms (Phlegm)	Yes	91	(20,1)	40	(44)	51	(56)	0,00 2	2,1	(1,3 - 3,3)
	No	36	(79,9)	22	(61,8)	13	(38,2)		1	
Respiratory Signs and Symptoms (Difficulty Breathing)	Yes	20	(4,4)	13	(65)	7	(35)	0,52 9	0,7	(0,3 - 1,9)
	No	43	(95,6)	25	(57,9)	18	(42,1)		1	
Respiratory Signs and Symptoms (Fatigue)	Yes	7	(1,5)	3	(42,9)	4	(57,1)	0,41 5	1,9	(0,4 - 8,5)
	No	44	(98,5)	26	(58,4)	18	(41,6)		1	
Low Weight at Birth	Yes	10	(22,3)	65	(64,4)	36	(35,6)	0,15 5	0,7	(0,5 - 1,1)
	No	35	(77,7)	19	(56,4)	15	(43,6)		1	
Vaccination Status	Non-Immunized	15	(34,1)	83	(53,9)	71	(46,1)	0,03 6	1,6	(1,0 - 2,5)
	Incomplete Immunization	36	(8,0)	15	(41,7)	21	(58,3)	0,01 0	2,6	(1,3 - 5,4)
	Immunization in Process	73	(16,2)	42	(57,5)	31	(42,5)	0,25 8	1,4	(0,8 - 2,4)
	Complete Immunization	18	(41,8)	12	(65,1)	66	(34,9)		1	

C. Characteristics of the Living Quarters, Home and Life Habits

Variable		n	(%)	Colonization (n = 189)				p	OR Raw	(IC95%)
				No		Yes				
				n	(%)	n	(%)			
Overcrowding	Yes	51	(11,3)	27	(52,9)	24	(47,1)	0,42 1	1,3	(0,7 - 2,3)
	No	40	(88,7)	23	(58,9)	16	(41,1)		1	
Shared Bedroom	Yes	35	(78,3)	20	(58,2)	14	(41,8)	0,99 6	1,0	(0,6 - 1,6)
	No	98	(21,7)	57	(58,2)	41	(41,8)		1	

Living with Smokers	Yes	61	(13,5)	38	(62,3)	23	(37,7)	0,48	0,8	(0,5 - 1,4)
	No	39	(86,5)	22	(57,5)	16	(42,5)		1	
Contact With Sick Person(s) (Otitis)	Yes	18	(4)	12	(66,7)	6	(33,3)	0,45	0,7	(0,3 - 1,9)
	No	43	(96)	25	(57,8)	18	(42,2)		1	
Contact With Sick Person(s) (Sinusitis)	Yes	22	(4,9)	13	(59,1)	9	(40,9)	0,93	1,0	(0,4 - 2,3)
	No	43	(95,1)	25	(58,1)	18	(41,9)	0	1	
Contact With Sick Person(s) (Bronchitis)	Yes	7	(1,5)	4	(57,1)	3	(42,9)	0,95	1,0	(0,2 - 4,7)
	No	44	(98,5)	25	(58,2)	18	(41,8)		1	
Contact With Sick Person(s) (Pneumonia)	Yes	5	(1,1)	3	(60)	2	(40)	0,93	0,9	(0,2 - 5,6)
	No	44	(98,9)	26	(58,2)	18	(41,8)	4	1	
Contact With Sick Person(s) (Meningitis)	Yes	2	(0,4)	0	(0)	2	(100)	--	--	--
	No	45	(99,6)	26	(58,4)	18	(41,6)		1	
Hospitalized Home Members	Yes	27	(6)	14	(51,9)	13	(48,1)	0,49	1,3	(0,6 - 2,9)
	No	42	(94)	24	(58,6)	17	(41,4)		1	
Assists to Child Care Center	Yes	17	(39,4)	91	(51,1)	87	(48,9)	0,01	1,6	(1,1 - 2,4)
	No	27	(60,6)	17	(62,8)	10	(37,2)	4	1	

-- Not Determined.

Table 3. Multivariate analysis of associated factors for *Streptococcus pneumoniae* nasopharyngeal colonization in 452 outpatient children of the Club Noel Children's Clinic, involved in the study, in 2019.

Variable		<i>p</i>	OR Adjusted	(IC95%)
Gender	Male	0,55 4	1,1	(0,7 - 1,7)
	Female		1	
Age in Years	0	0,11 5	2,8	(0,8 - 10,2)
	1	0,17 3	2,1	(0,7 - 6,4)
	2	0,03 1	3,1	(1,1 - 8,9)
	3	0,06 8	2,6	(0,9 - 7,1)
	4	0,20 1	1,9	(0,7 - 5,4)
	5		1	
Race or Culture	Native	0,03 5	2,4	(1,1 - 5,4)
	Afro-Colombian	0,34 8	0,7	(0,4 - 1,4)
	Mestizo-Colombian		1	
Socioeconomic Stratum	1	0,15 7	2,2	(0,7 - 6,3)
	2	0,36 5	1,6	(0,6 - 4,6)
	3	0,38 2	1,6	(0,6 - 4,7)
	4, 5 y 6		0,0	
Severe Underlying Disease (Total)	Yes	0,20 7	1,6	(0,8 - 3,3)
	No		1	
Previous Respiratory Disease (Asthma)	Yes	0,11 7	1,7	(0,9 - 3,4)
	No		1	
Previous Respiratory Disease (Rhinitis)	Yes	0,18 0	1,9	(0,8 - 4,6)
	No		1	
Respiratory Signs and Symptoms (Nasal Secretion)	Yes	0,00 3	2,1	(1,3 - 3,4)
	No		1	
Respiratory Signs and Symptoms (Sneezing)	Yes	0,23 0	0,7	(0,4 - 1,2)

	No		1	
Respiratory Signs and Symptoms (Cough)	Yes	0,10 2	1,6	(0,9 - 2,7)
	No		1	
Respiratory Signs and Symptoms (Phlegm)	Yes	0,80 8	1,1	(0,6 - 2,0)
	No		1	
Immunization Status	Non-Immunized	0,04 9	1,7	(1,0 - 2,7)
	Incomplete Immunization	0,00 7	3,0	(1,3 - 6,7)
	Immunization in Process	0,25 6	1,8	(0,6 - 5,1)
	Complete Immunization		1	
Overcrowding	Yes	0,39 5	1,3	(0,7 - 2,6)
	No		1	
Assist to Child Care Center	Yes	0,03 9	1,8	(1,0 - 3,2)
	No		1	

Table 4. Antimicrobial susceptibility profiles of *Streptococcus pneumoniae* colonizing strain, isolates of the 452 patients involved in the study.

Antimicrobial Agent	<i>S. pneumoniae</i> (n = 189)					
	Resistant		Intermediate		Susceptible	
	n	(%)	n	(%)	n	(%)
Benzyl-penicillin (Meningitis)	109	(57,7)	0	(0)	80	(42,3)
Erythromycin	77	(40,7)	0	(0)	112	(59,3)
Tetracycline	68	(36,0)	0	(0)	121	(64,0)
Trimethoprim/sulfamethoxazole	47	(24,9)	15	(7,9)	127	(67,2)
Clindamycin	46	(24,3)	5	(2,6)	138	(73,0)
Benzyl-penicillin (Oral)	23	(12,2)	86	(45,5)	80	(42,3)
Ceftriaxone (Meningitis)	17	(9,0)	14	(7,4)	158	(83,6)
Cefotaxime (Meningitis)	15	(7,9)	14	(7,4)	160	(84,7)
Ceftriaxone (Another)	10	(5,3)	7	(3,7)	172	(91,0)
Cefotaxime (Another)	9	(4,8)	6	(3,2)	174	(92,1)
Benzyl-penicillin (Pneumonia)	4	(2,1)	5	(2,6)	180	(95,2)
Vancomycin	0	(0)	0	(0)	189	(100)
Chloramphenicol	0	(0)	0	(0)	189	(100)
Linezolid	0	(0)	0	(0)	189	(100)
Tigecycline	0	(0)	0	(0)	189	(100)

Levofloxacin	0	(0)	0	(0)	189	(100)
Moxifloxacin	0	(0)	0	(0)	189	(100)
Rifampicin	0	(0)	0	(0)	189	(100)

Figure 2. Proportion of nasopharyngeal colonization by *Streptococcus pneumoniae* and immunization status according to the age in months (and years) of participating children. Southwestern of Colombia, 2019.

